CalciMedica, Inc. Regains Nasdaq Minimum Bid Price Compliance

What Happened

• CalciMedica, Inc. (CALC) announced in an 8-K that Nasdaq has determined the company regained compliance with Listing Rule 5550(a)(2), the $1.00 minimum bid price requirement.
• The company received a Nasdaq letter on September 15, 2026, confirming that the closing bid price of its common stock was $1.00 or greater for 10 consecutive business days from August 31, 2026 through September 14, 2026.
• CalciMedica had previously received a non-compliance notice on March 16, 2026 and had a 180-calendar-day cure period that expired on September 14, 2026.

Key Details

• Nasdaq rule involved: Listing Rule 5550(a)(2) (minimum $1.00 bid price).
• Non-compliance notice date: March 16, 2026; cure period end date: September 14, 2026.
• Compliance period: 10 consecutive business days with closing bid ≥ $1.00 from August 31–September 14, 2026.
• Nasdaq confirmation letter received by the company on September 15, 2026; as of this 8-K filing the company has no outstanding deficiency notices from Nasdaq.

Why It Matters

• Regaining compliance removes the immediate Nasdaq deficiency tied to the stock’s minimum bid price and avoids the near-term delisting process related to that specific rule.
• For investors, maintaining Nasdaq listing typically supports liquidity and continued access to institutional and retail markets; the company’s current status shows the specific deficiency has been cured.
• This filing is a factual regulatory update—no new financial results or management changes were reported.